Compare DexCom, Inc. (DXCM) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Jumia Technologies AG - ADR — how do they compare? DexCom, Inc. trades at $83.88 (market cap $31.86B), while Jumia Technologies AG - ADR trades at $6.24 (market cap $865.90M). The key difference: DexCom, Inc. is far larger — about 36.8× Jumia Technologies AG - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Jumia Technologies AG - ADR for 28 Days on average.
| DXCM | JMIA | |
|---|---|---|
Market Cap | $31.86B | $865.90M |
Volume | 3,607,070 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $14.60 |
52-Week Low | $54.84 | $5.69 |
Typical Hold Time | 62 Days | 28 Days |
Enterprise Value | $31.32B | $831.54M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
JMIA stock trades at $6.315, down 6.31% today, amid a bearish technical signal. The company reported revenue of $188.93M in 2025 with a net loss of $61.55M, though losses are narrowing year-over-year. Analyst consensus is bullish with a $12.00 price target, and recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
The outlook hinges on JMIA achieving profitability targets, with upside potential from analyst targets but risks from persistent losses and high valuation multiples. Execution on cost control and African e-commerce growth are critical for stock performance, while cash flow volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
